A randomized controlled study of the effects of 17Beta-estradiol-dydrogesterone on plasma homocysteine in postmenopausal women
Objective: To investigate the effects of oral 17β-estradiol (E2) -dydrogesterone on fasting plasma homocysteine concentrations in healthy postmenopausal women. Methods: We studied 27 postmenopausal women who were assigned randomly to either a treatment group ( n = 14) or a control group ( n = 13). D...
Gespeichert in:
| Veröffentlicht in: | Obstetrics and gynecology (New York. 1953) 1998-03, Vol.91 (3), p.432-436 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 436 |
|---|---|
| container_issue | 3 |
| container_start_page | 432 |
| container_title | Obstetrics and gynecology (New York. 1953) |
| container_volume | 91 |
| creator | Mijatovic, Velja Kenemans, Peter Jakobs, Cornelis Van Baal, W.Marchien Peters-Muller, Edith R. Van der Mooren, Marius J. |
| description | Objective: To investigate the effects of oral 17β-estradiol (E2) -dydrogesterone on fasting plasma homocysteine concentrations in healthy postmenopausal women.
Methods: We studied 27 postmenopausal women who were assigned randomly to either a treatment group (
n = 14) or a control group (
n = 13). During the first 12 months of the study, treatment consisted of oral E2, 1 mg daily, combined sequentially with dydrogesterone 5 or 10 mg (14 days per 28-day treatment cycle). Thereafter, women were treated with oral E2,2 mg daily, combined sequentially with dydrogesterone, 10 mg daily (14 days per 28-day treatment cycle) for a period of 3 months. The control group received no treatment. Fasting plasma total homocysteine concentrations were determined at baseline and 3, 12, and 15 months after study entry.
Results: At baseline, plasma homocysteine levels did not differ between the groups. After 15 months of hormone treatment mean plasma homocysteine concentration was lowered by 12.6% compared with baseline (
P < .001; analysis of variance for repeated measures). Plasma homocysteine levels were not altered in the control group. The interaction between treatment and time for homocysteine levels was significantly different between the groups (
P < .001; analysis of variance for repeated measures). The decrease in plasma homocysteine levels correlated inversely with the increase in serum E2 levels after 3 and 12 months of hormone treatment (
r = −.54,
P < .05 and
r = −.56,
P < .05, respectively).
Conclusion: Plasma fasting homocysteine concentrations are lowered by E2-dydrogesterone therapy in postmenopausal women. |
| doi_str_mv | 10.1016/S0029-7844(97)00704-7 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_79715802</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0029784497007047</els_id><sourcerecordid>79715802</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4051-794a86fbe2e2471e415aefaa1a1553ea9ef686e94025f729cbdc5b9a2dd054203</originalsourceid><addsrcrecordid>eNqFkUGPFCEQhYnRrLOrP2GTPhk9oAUNTXMyuxtXTTbxoCbeCAPVDko3I3Q7GQ_-dpmdyV49EHjFe0Xlg5BLBq8ZsO7NZwCuqeqFeKnVKwAFgqpHZMV61VLett8ek9WD5Sk5L-UHQA3q9oycaaEPvhX5e9VkO_k0hj_oG5emOacY67HMi983aWjmDTY4DOjmcpBMXeNsKZY5Wx9SpH7vc_peNeY0YZOmZhttGW2zSWNy-1oPtRxqOZV5xClt7VJsbHapimfkyWBjween_YJ8vX335eYDvfv0_uPN1R11AiSjSgvbd8MaOXKhGAomLQ7WMsukbNFqHLq-Qy2Ay0Fx7dbeybW23HuQgkN7QV4c-25z-rXUYc0YisMY7YRpKUZpxWQPvBrl0ehyKiXjYLY5jDbvDQNz4G7uuZsDVKOVueduVM1dnh5Y1iP6h9QJdL0Xx_tdipVU-RmXHWazQRvnTe0C0HEJlGndQ1sVrYuzGnt7jGGF8zvURHEBJ4c-5Pojxqfwn8H-AXFVpPU</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>79715802</pqid></control><display><type>article</type><title>A randomized controlled study of the effects of 17Beta-estradiol-dydrogesterone on plasma homocysteine in postmenopausal women</title><source>MEDLINE</source><source>Journals@Ovid Complete</source><creator>Mijatovic, Velja ; Kenemans, Peter ; Jakobs, Cornelis ; Van Baal, W.Marchien ; Peters-Muller, Edith R. ; Van der Mooren, Marius J.</creator><creatorcontrib>Mijatovic, Velja ; Kenemans, Peter ; Jakobs, Cornelis ; Van Baal, W.Marchien ; Peters-Muller, Edith R. ; Van der Mooren, Marius J.</creatorcontrib><description>Objective: To investigate the effects of oral 17β-estradiol (E2) -dydrogesterone on fasting plasma homocysteine concentrations in healthy postmenopausal women.
Methods: We studied 27 postmenopausal women who were assigned randomly to either a treatment group (
n = 14) or a control group (
n = 13). During the first 12 months of the study, treatment consisted of oral E2, 1 mg daily, combined sequentially with dydrogesterone 5 or 10 mg (14 days per 28-day treatment cycle). Thereafter, women were treated with oral E2,2 mg daily, combined sequentially with dydrogesterone, 10 mg daily (14 days per 28-day treatment cycle) for a period of 3 months. The control group received no treatment. Fasting plasma total homocysteine concentrations were determined at baseline and 3, 12, and 15 months after study entry.
Results: At baseline, plasma homocysteine levels did not differ between the groups. After 15 months of hormone treatment mean plasma homocysteine concentration was lowered by 12.6% compared with baseline (
P < .001; analysis of variance for repeated measures). Plasma homocysteine levels were not altered in the control group. The interaction between treatment and time for homocysteine levels was significantly different between the groups (
P < .001; analysis of variance for repeated measures). The decrease in plasma homocysteine levels correlated inversely with the increase in serum E2 levels after 3 and 12 months of hormone treatment (
r = −.54,
P < .05 and
r = −.56,
P < .05, respectively).
Conclusion: Plasma fasting homocysteine concentrations are lowered by E2-dydrogesterone therapy in postmenopausal women.</description><identifier>ISSN: 0029-7844</identifier><identifier>EISSN: 1873-233X</identifier><identifier>DOI: 10.1016/S0029-7844(97)00704-7</identifier><identifier>PMID: 9491873</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Dydrogesterone - therapeutic use ; Estradiol - therapeutic use ; Estrogen Replacement Therapy ; Female ; Homocysteine - blood ; Humans ; Middle Aged ; Postmenopause - blood ; Treatment Outcome</subject><ispartof>Obstetrics and gynecology (New York. 1953), 1998-03, Vol.91 (3), p.432-436</ispartof><rights>1998</rights><rights>1998 The American College of Obstetricians and Gynecologists</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4051-794a86fbe2e2471e415aefaa1a1553ea9ef686e94025f729cbdc5b9a2dd054203</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/9491873$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Mijatovic, Velja</creatorcontrib><creatorcontrib>Kenemans, Peter</creatorcontrib><creatorcontrib>Jakobs, Cornelis</creatorcontrib><creatorcontrib>Van Baal, W.Marchien</creatorcontrib><creatorcontrib>Peters-Muller, Edith R.</creatorcontrib><creatorcontrib>Van der Mooren, Marius J.</creatorcontrib><title>A randomized controlled study of the effects of 17Beta-estradiol-dydrogesterone on plasma homocysteine in postmenopausal women</title><title>Obstetrics and gynecology (New York. 1953)</title><addtitle>Obstet Gynecol</addtitle><description>Objective: To investigate the effects of oral 17β-estradiol (E2) -dydrogesterone on fasting plasma homocysteine concentrations in healthy postmenopausal women.
Methods: We studied 27 postmenopausal women who were assigned randomly to either a treatment group (
n = 14) or a control group (
n = 13). During the first 12 months of the study, treatment consisted of oral E2, 1 mg daily, combined sequentially with dydrogesterone 5 or 10 mg (14 days per 28-day treatment cycle). Thereafter, women were treated with oral E2,2 mg daily, combined sequentially with dydrogesterone, 10 mg daily (14 days per 28-day treatment cycle) for a period of 3 months. The control group received no treatment. Fasting plasma total homocysteine concentrations were determined at baseline and 3, 12, and 15 months after study entry.
Results: At baseline, plasma homocysteine levels did not differ between the groups. After 15 months of hormone treatment mean plasma homocysteine concentration was lowered by 12.6% compared with baseline (
P < .001; analysis of variance for repeated measures). Plasma homocysteine levels were not altered in the control group. The interaction between treatment and time for homocysteine levels was significantly different between the groups (
P < .001; analysis of variance for repeated measures). The decrease in plasma homocysteine levels correlated inversely with the increase in serum E2 levels after 3 and 12 months of hormone treatment (
r = −.54,
P < .05 and
r = −.56,
P < .05, respectively).
Conclusion: Plasma fasting homocysteine concentrations are lowered by E2-dydrogesterone therapy in postmenopausal women.</description><subject>Dydrogesterone - therapeutic use</subject><subject>Estradiol - therapeutic use</subject><subject>Estrogen Replacement Therapy</subject><subject>Female</subject><subject>Homocysteine - blood</subject><subject>Humans</subject><subject>Middle Aged</subject><subject>Postmenopause - blood</subject><subject>Treatment Outcome</subject><issn>0029-7844</issn><issn>1873-233X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1998</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkUGPFCEQhYnRrLOrP2GTPhk9oAUNTXMyuxtXTTbxoCbeCAPVDko3I3Q7GQ_-dpmdyV49EHjFe0Xlg5BLBq8ZsO7NZwCuqeqFeKnVKwAFgqpHZMV61VLett8ek9WD5Sk5L-UHQA3q9oycaaEPvhX5e9VkO_k0hj_oG5emOacY67HMi983aWjmDTY4DOjmcpBMXeNsKZY5Wx9SpH7vc_peNeY0YZOmZhttGW2zSWNy-1oPtRxqOZV5xClt7VJsbHapimfkyWBjween_YJ8vX335eYDvfv0_uPN1R11AiSjSgvbd8MaOXKhGAomLQ7WMsukbNFqHLq-Qy2Ay0Fx7dbeybW23HuQgkN7QV4c-25z-rXUYc0YisMY7YRpKUZpxWQPvBrl0ehyKiXjYLY5jDbvDQNz4G7uuZsDVKOVueduVM1dnh5Y1iP6h9QJdL0Xx_tdipVU-RmXHWazQRvnTe0C0HEJlGndQ1sVrYuzGnt7jGGF8zvURHEBJ4c-5Pojxqfwn8H-AXFVpPU</recordid><startdate>199803</startdate><enddate>199803</enddate><creator>Mijatovic, Velja</creator><creator>Kenemans, Peter</creator><creator>Jakobs, Cornelis</creator><creator>Van Baal, W.Marchien</creator><creator>Peters-Muller, Edith R.</creator><creator>Van der Mooren, Marius J.</creator><general>Elsevier Inc</general><general>The American College of Obstetricians and Gynecologists</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>199803</creationdate><title>A randomized controlled study of the effects of 17Beta-estradiol-dydrogesterone on plasma homocysteine in postmenopausal women</title><author>Mijatovic, Velja ; Kenemans, Peter ; Jakobs, Cornelis ; Van Baal, W.Marchien ; Peters-Muller, Edith R. ; Van der Mooren, Marius J.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4051-794a86fbe2e2471e415aefaa1a1553ea9ef686e94025f729cbdc5b9a2dd054203</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1998</creationdate><topic>Dydrogesterone - therapeutic use</topic><topic>Estradiol - therapeutic use</topic><topic>Estrogen Replacement Therapy</topic><topic>Female</topic><topic>Homocysteine - blood</topic><topic>Humans</topic><topic>Middle Aged</topic><topic>Postmenopause - blood</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Mijatovic, Velja</creatorcontrib><creatorcontrib>Kenemans, Peter</creatorcontrib><creatorcontrib>Jakobs, Cornelis</creatorcontrib><creatorcontrib>Van Baal, W.Marchien</creatorcontrib><creatorcontrib>Peters-Muller, Edith R.</creatorcontrib><creatorcontrib>Van der Mooren, Marius J.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Obstetrics and gynecology (New York. 1953)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Mijatovic, Velja</au><au>Kenemans, Peter</au><au>Jakobs, Cornelis</au><au>Van Baal, W.Marchien</au><au>Peters-Muller, Edith R.</au><au>Van der Mooren, Marius J.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>A randomized controlled study of the effects of 17Beta-estradiol-dydrogesterone on plasma homocysteine in postmenopausal women</atitle><jtitle>Obstetrics and gynecology (New York. 1953)</jtitle><addtitle>Obstet Gynecol</addtitle><date>1998-03</date><risdate>1998</risdate><volume>91</volume><issue>3</issue><spage>432</spage><epage>436</epage><pages>432-436</pages><issn>0029-7844</issn><eissn>1873-233X</eissn><abstract>Objective: To investigate the effects of oral 17β-estradiol (E2) -dydrogesterone on fasting plasma homocysteine concentrations in healthy postmenopausal women.
Methods: We studied 27 postmenopausal women who were assigned randomly to either a treatment group (
n = 14) or a control group (
n = 13). During the first 12 months of the study, treatment consisted of oral E2, 1 mg daily, combined sequentially with dydrogesterone 5 or 10 mg (14 days per 28-day treatment cycle). Thereafter, women were treated with oral E2,2 mg daily, combined sequentially with dydrogesterone, 10 mg daily (14 days per 28-day treatment cycle) for a period of 3 months. The control group received no treatment. Fasting plasma total homocysteine concentrations were determined at baseline and 3, 12, and 15 months after study entry.
Results: At baseline, plasma homocysteine levels did not differ between the groups. After 15 months of hormone treatment mean plasma homocysteine concentration was lowered by 12.6% compared with baseline (
P < .001; analysis of variance for repeated measures). Plasma homocysteine levels were not altered in the control group. The interaction between treatment and time for homocysteine levels was significantly different between the groups (
P < .001; analysis of variance for repeated measures). The decrease in plasma homocysteine levels correlated inversely with the increase in serum E2 levels after 3 and 12 months of hormone treatment (
r = −.54,
P < .05 and
r = −.56,
P < .05, respectively).
Conclusion: Plasma fasting homocysteine concentrations are lowered by E2-dydrogesterone therapy in postmenopausal women.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>9491873</pmid><doi>10.1016/S0029-7844(97)00704-7</doi><tpages>5</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0029-7844 |
| ispartof | Obstetrics and gynecology (New York. 1953), 1998-03, Vol.91 (3), p.432-436 |
| issn | 0029-7844 1873-233X |
| language | eng |
| recordid | cdi_proquest_miscellaneous_79715802 |
| source | MEDLINE; Journals@Ovid Complete |
| subjects | Dydrogesterone - therapeutic use Estradiol - therapeutic use Estrogen Replacement Therapy Female Homocysteine - blood Humans Middle Aged Postmenopause - blood Treatment Outcome |
| title | A randomized controlled study of the effects of 17Beta-estradiol-dydrogesterone on plasma homocysteine in postmenopausal women |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-08T03%3A32%3A11IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=A%20randomized%20controlled%20study%20of%20the%20effects%20of%2017Beta-estradiol-dydrogesterone%20on%20plasma%20homocysteine%20in%20postmenopausal%20women&rft.jtitle=Obstetrics%20and%20gynecology%20(New%20York.%201953)&rft.au=Mijatovic,%20Velja&rft.date=1998-03&rft.volume=91&rft.issue=3&rft.spage=432&rft.epage=436&rft.pages=432-436&rft.issn=0029-7844&rft.eissn=1873-233X&rft_id=info:doi/10.1016/S0029-7844(97)00704-7&rft_dat=%3Cproquest_cross%3E79715802%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=79715802&rft_id=info:pmid/9491873&rft_els_id=S0029784497007047&rfr_iscdi=true |